Haemonetics (HAE) Depreciation & Amortization (CF) (2009 - 2026)

Haemonetics has reported Depreciation & Amortization (CF) for 18 years, with the latest figure at $27.3 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 3.15% year-over-year to $27.3 million; the trailing twelve-month figure through Mar 2026 stood at $111.7 million (down 3.35% YoY), and the FY2026 full-year result was $111.7 million, down 3.35% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $27.3 million, roughly flat from $27.4 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $29.2 million in Q3 2024, with the low at $22.4 million in Q3 2022.
• Average Depreciation & Amortization (CF) over 5 years is $25.9 million, with a median of $26.1 million recorded in 2022.
• Year-over-year, Depreciation & Amortization (CF) slipped 10.33% in 2022 and grew 26.96% in 2024.
• Tracing HAE's Depreciation & Amortization (CF) over 5 years: stood at $23.6 million in 2022, then retreated by 0.17% to $23.5 million in 2023, then advanced by 23.35% to $29.0 million in 2024, then retreated by 5.65% to $27.4 million in 2025, then decreased by 0.24% to $27.3 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $27.3 million (Q1 2026), $27.4 million (Q4 2025), and $28.3 million (Q3 2025), per Business Quant data.

Peer Comparison